The Wnt/β-catenin pathway plays important roles in the differentiation of multiple cell types, including mesenchymal stem cells. Using a cell-based chemical screening assay with a synthetic chemical library of 270 000 compounds, we identified the compound SKL2001 as a novel agonist of the Wnt/β-catenin pathway and uncovered its molecular mechanism of action. SKL2001 upregulated β-catenin responsive transcription by increasing the intracellular β-catenin protein level and inhibited the phosphorylation of β-catenin at residues Ser33/37/Thr41 and Ser45, which would mark it for proteasomal degradation, without affecting CK1 and GSK-3β enzyme activities. Biochemical analysis revealed that SKL2001 disrupted the Axin/β-catenin interaction, which is a critical step for CK1-and GSK-3β-mediated phosphorylation of β-catenin at Ser33/37/Thr41 and Ser45. The treatment of mesenchymal stem cells with SKL2001 promoted osteoblastogenesis and suppressed adipocyte differentiation, both of which were accompanied by the activation of Wnt/β-catenin pathway. Our findings provide a new strategy to regulate mesenchymal stem cell differentiation by modulation of the Wnt/β-catenin pathway.
Introduction
The Wnt/β-catenin pathway plays an important role in cell proliferation, morphology, motility, fate determination, axis formation, and organ development [1] [2] [3] . The level of intracellular β-catenin, which is a key regulator of the Wnt/β-catenin pathway, is controlled by the proteasomal degradation pathway in a phosphorylation-dependent manner. Casein kinase 1 (CK1) and glycogen synthase kinase-3β (GSK-3β) sequentially catalyze β-catenin phosphorylation at residues Ser45, Thr 41, Ser37, and Ser33 in a complex with adenomatous polyposis coli (APC) and Axin [4, 5] . Phosphorylated β-catenin is then recognized by the F-box β-transducin repeat-containing protein (β-TrCP), a component of the ubiquitin ligase complex, leading to its ubiquitindependent degradation by the proteasome [6, 7] . Upon Wnt stimulation, Wnt, the Frizzled (Fz) receptor, and the low-density lipoprotein receptor-related protein5/6 (LRP5/6) co-receptor form a complex. The recruitment of Dishevelled (Dvl) to Fz leads to LRP5/6 phosphorylation, which induces the association of the Axin complex with phosphorylated LRP5/6, thereby inhibiting Axinmediated β-catenin phosphorylation and stabilizing intracellular β-catenin [8] .
Multipotent mesenchymal stem cells are able to dif-ferentiate into osteoblasts, adipocytes, chondrocytes, and myoblasts [9, 10] . The differentiation of mesenchymal stem cells is regulated by interaction with specific extracellular mediators. Recent studies have implicated Wnt signaling in the commitment of mesenchymal stem cells to their various lineages. For example, the Wnt/β-catenin pathway promotes osteogenesis by stimulating Runx2 gene expression [11] and represses adipogenic differentiation of mesenchymal stem cells through the downregulation of adipogenic factors [12, 13] . Wnt signaling also suppresses the induction of Sox9, a key regulator of chondrogenesis, which results in the inhibition of mesenchymal stem cell differentiation to chondrocytes [14, 15] . In addition, Wnt signaling upregulates two key regulators of myogenesis, MyoD and Myf 5, in the induction of myogenic differentiation [16] .
In this study, we used a forward chemical genetic approach to identify a small molecule capable of activating the Wnt/β-catenin pathway. SKL2001 stabilizes intracellular β-catenin via disruption of the Axin/β-catenin interaction, and can be applied to regulate mesenchymal stem cell differentiation.
Results

Identification of a small-molecule activator of the Wnt/ β-catenin pathway
To screen for small molecules that modulate the Wnt/ β-catenin pathway, we generated HEK293 reporter cells that were stably transfected with hFZ-1 expression plasmid and TOPflash, a synthetic β-catenin/Tcf-dependent luciferase reporter [17] . Screening a small molecule library containing ~270 000 compounds using these HEK293 reporter cells revealed that SKL2001 (5-furan2yl-isoxazole-3-carboxylic acid (3-imidazol-1yl-propyl)-amide) strongly activated β-catenin responsive transcription (CRT) ( Figure 1A and 1B). SKL2001 upregulated TOPflash reporter activity in a dose-dependent manner, whereas it did not affect the activity of FOPFlash, a negative control reporter with mutated β-catenin/Tcfbinding elements, in HEK293 control cells ( Figure 1C ). SKL2001 did not affect either NF-κB or p53 reporter activity (Supplementary information, Figure S1 ). In addition, SKL2001 upregulated the expression of Axin2, which is a downstream target of the Wnt/β-catenin pathway (Supplementary information, Figure S2 ). These results indicate that SKL2001 is a specific activator of the Wnt/β-catenin pathway.
We next investigated the effect of SKL2001 on the level of intracellular β-catenin by western blotting using anti-β-catenin antibodies. Consistent with previous data [18, 19] , the β-catenin level was increased by incubation with Wnt3a-conditioned medium (Wnt3a-CM) or LiCl, a GSK-3β inhibitor ( Figure 1D ). Interestingly, treatment with SKL2001 resulted in an increase in β-catenin in both the cytosolic and nuclear fractions, consistent with its effect on CRT ( Figure 1D ). However, the mRNA level of β-catenin was unchanged in response to various concentrations of SKL2001 ( Figure 1E ). These results suggest that SKL2001 activates Wnt/β-catenin signaling by increasing the stability of  the β-catenin protein.
SKL2001 inhibits β-catenin phosphorylation without affecting GSK-3β activity
Previous studies have suggested that the phosphorylation of β-catenin at specific N-terminal Ser/Thr residues and its subsequent interaction with β-TrCP result in the degradation of β-catenin [20] . Therefore, we examined the change in the phosphorylation status at these residues in response to SKL2001 treatment in HEK293 cells. In agreement with previous data [21] , western blot analysis with phospho-specific anti-β-catenin antibodies showed that Wnt3a-CM and LiCl inhibited the phosphorylation of β-catenin at the Ser33/37/Thr41 residues ( Figure  2A ). Treatment with SKL2001 also inhibited Ser33/37/ Thr41 phosphorylation (Figure 2A ) without affecting the phosphorylation of GSK-3β at Ser9 (Supplementary information, Figure S3 ), indicating that this inhibition of β-catenin phosphorylation may be involved in the SKL2001-mediated β-catenin stabilization. Interestingly, Wnt3a-CM and SKL2001 prevented the phosphorylation of β-catenin at residues Thr41 and Ser45, whereas LiCl did not affect the phosphorylation of these residues (Figure 2A) . Because the N-terminal Ser/Thr residues of β-catenin are phosphorylated by GSK-3β, we examined the in vitro effect of SKL2001 on β-catenin phosphorylation by this kinase, using purified β-catenin, CK1, and GSK-3β. As shown in Figure 2B , SKL2001 did not affect GSK-3β-mediated β-catenin phosphorylation in vitro; in contrast, 6-bromoindirubin-3′-oxim (BIO), an inhibitor of GSK-3β [22] , potently prevented the phosphorylation of β-catenin by GSK-3β. In addition, when SKL2001 was assayed at 10 µM against a panel of recombinant kinases, it did not inhibit the activity of any tested kinase, including GSK-3β ( Figure 2C ). Under these conditions, 1-(4-aminofurazan-3-yl)-5-dialkylaminomethyl-1H- [1, 2, 3] triazole-4-carboxylic acid (Novo), which is an ATP-competitive inhibitor of GSK-3β [23] , selectively inhibited GSK-3β ( Figure 2C ). Together, these results indicate that SKL2001 inhibits β-catenin phosphorylation without affecting GSK-3β activity.
SKL2001 disrupts the Axin/β-catenin interaction
Axin regulates GSK-3β-mediated β-catenin phospho-
npg rylation through the interaction with CK1/GSK-3β and β-catenin [24] . To further investigate the mechanism of activation of the Wnt/β-catenin pathway by SKL2001, we first tested the effect of SKL2001 on the level of Axin. As shown in Figure 3A , the expression of Axin was unchanged by any of the concentrations of SKL2001 used ( Figure 3A ). We next examined whether SKL2001 inhibits the interaction of β-catenin with Axin. Using purified fragment of Axin (362-500) and β-catenin, we demonstrated that the Axin/β-catenin interaction was disrupted by treatment with SKL2001 ( Figure 3B , lanes 1 and 2); however, this effect was abolished with increased amounts of Axin ( Figure 3B , lanes 3 to 10). We also performed immunoprecipitation assays in HEK293 cells to further confirm that SKL2001 inhibits the interaction of Axin and β-catenin. As shown in Figure 3C , the coimmunoprecipitation of β-catenin with Axin was prevented by SKL2001. In accordance with our in vitro data, SKL2001-mediated CRT activation and β-catenin stabilization were abrogated by overexpression of Axin in HEK293 reporter cells ( Figure 3D and Supplementary information, Figure S4A ). Notably, SKL2001 was not able to activate CRT in Axin null SNU475 cells (Supplementary information, Figure S4B ). Moreover, when we depleted the endogenous β-catenin using siRNA, SKL2001 was unable to activate the Wnt/β-catenin pathway (Supplementary information, Figure S5 ).
To examine whether intracellular β-catenin is specifically stabilized by SKL2001, we synthesized an inactive derivative of SKL2001 called SKL11324 (Supplementary information, Figure S6A ). As shown in the Supplementary information ( Figure S6B and S6C), SKL11324 neither disrupted Axin/β-catenin interaction nor activated the Wnt/β-catenin pathway. Taken together, these results suggest that the disruption of the Axin/β-catenin interaction is the molecular basis for SKL2001-mediated β-catenin stabilization.
SKL2001 induces osteoblast differentiation
Activation of the Wnt/β-catenin pathway, followed by an accumulation of intracellular β-catenin, increases bone mass via the stimulation of osteoblastogenesis [25, 26] . Given that SKL2001 stimulates the Wnt/β-catenin pathway, we hypothesized that SKL2001 would also promote the differentiation of multipotent mesenchymal stem cells to osteoblasts. To explore this hypothesis, we first examined whether multipotent mesenchymal ST2 cells are capable of activating the Wnt/β-catenin pathway when treated with SKL2001. As expected, ST2 cells treated with SKL2001 showed a robust, concentrationdependent increase in TOPflash reporter activity, without a substantial change in FOPflash reporter activity (Figure 4A ). In addition, the intracellular β-catenin level, which is an indicator of the activation status of the Wnt/ β-catenin pathway, also increased after incubation with SKL2001 in ST2 cells ( Figure 4B and 4C) . These results suggest that Wnt/β-catenin signaling is stimulated in response to SKL2001 in ST2 cells. We next examined whether SKL2001 promotes osteoblast differentiation. The incubation of ST2 and human primary mesenchymal stem cells with SKL2001 led to a dose-dependent rise in alkaline phosphatase (ALP) activity, which is an indicator of osteoblastogenesis ( Figure 4D and Supplementary information, Figure S7 ). We also analyzed the mRNA expression of established osteoblast markers in ST2 cells treated with SKL2001 by semi-quantitative reverse transcriptase-PCR. Consistent with the increase in ALP activity, the mRNA expression of ALP was markedly . Cytosolic fractions were prepared and subjected to western blot analysis with anti-phospho-p45/41-β-catenin, anti-phospho-p33/37/41-β-catenin or anti-β-catenin antibody. The same amount of β-catenin was loaded in each lane. (B) SKL2001 does not affect GSK-3β-mediated β-catenin phosphorylation. GST-β-catenin (100 ng) was incubated with purified GSK3β and CK1 at the indicated concentrations of SKL2001 or BIO (5 µM). The samples were analyzed by western blotting with anti-phospho-p33/37/41-β-catenin antibody. The blot was reprobed with anti-β-catenin antibody as a loading control. (C) Recombinant kinase activity at 10 µM of SKL2001 or Novo. Kinase assays were performed as described in Materials and Methods.
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npg elevated in response to SKL2001 ( Figure 4E ). Moreover, SKL2001 induced the mRNA expression of other osteoblast markers such as type I collagen and Runx2 ( Figure  4E ), suggesting that SKL2001 induces osteoblastogenesis by activating the Wnt/β-catenin pathway. The stimulatory effect of SKL2001 on osteoblastogenesis was further supported by the observation that mineralization, as assessed by Alizarin red staining, was increased in ST2 cells treated with SKL2001 ( Figure 4F ).
SKL2001 suppresses preadipocyte differentiation
Wnt signaling represses preadipocyte differentiation, the alternative mesenchymal differentiation pathway, which is accompanied by the downregulation of master adipogenic transcription factors, such as C/EBPα and PPARγ [12, 13] . Therefore, we examined whether the activation of Wnt/β-catenin signaling by SKL2001 suppressed adipogenic differentiation. SKL2001 consistently induced the accumulation of intracellular β-catenin ( Figure 5A ) and inhibited the expression of C/EBPα and PPARγ, which was upregulated by incubation with dexamethasone and insulin (MDI) in 3T3-L1 preadipocytes ( Figure  5B ). The exposure of 3T3-L1 and ST2 cells to SKL2001 resulted in a concentration-dependent decrease in lipid droplet accumulation in response to MDI as visualized by Oil Red O staining ( Figure 5C and Supplementary information, Figure S8) ; these results are similar to the cellular response to the activation of Wnt/β-catenin signaling.
Discussion
The Wnt/β-catenin pathway is involved in the devel- npg opment and maintenance of many organs and tissues, including the bone [27, 28] . The function of β-catenin, a key effector of the Wnt/β-catenin pathway, is determined by its N-terminal phosphorylation state, specifically residues Ser33/37. The phosphorylation of these residues is a prerequisite for the subsequent ubiquitination and degradation of β-catenin. In this study, a screen of 270 000 compounds produced one novel compound, SKL2001, which specifically activated β-CRT in a dose-dependent manner. SKL2001 inhibited the phosphorylation of β-catenin at residues Ser33/37/Thr41/Ser45, leading to an increased level of intracellular β-catenin. Several small molecules have been reported to induce the accumulation of intracellular β-catenin by inhibiting GSK-3β activity [22, 29, 30] . Because GSK-3β is involved in multiple signaling pathways other than Wnt/β-catenin signaling, GSK-3β inhibitors are less than ideal drugs, as they could have unexpected effects on the cell and/or model organisms. In addition, although pyrimidine analogs have been identified as agonist of the Wnt/β-catenin pathway, their molecular targets and mechanisms of action are still unknown [31] . In our study, SKL2001 did not affect GSK-3β activity in regard to β-catenin phosphorylation at Ser33/37/Thr41 residues in vitro, suggesting that a novel mechanism, not dependent on the inhibition of GSK-3β activity, may mediate the inhibition of β-catenin phosphorylation by SKL2001 in cells.
The scaffolding protein Axin interacts with GSK-3β, CK1, and β-catenin through separate domains and coordinates sequential phosphorylation of β-catenin at Ser45 by CK1 and then at Ser33/37/Thr41 by GSK-3β [32] . The interaction of various Wnts (Wnt1, Wnt3a, and Wnt8) with their receptors (Fz) and co-receptors (LRP/5/6) triggers the recruitment of Axin to LRP6, promoting the dissociation of β-catenin from Axin and thereby inhibiting β-catenin phosphorylation and its subsequent degradation [33, 34] . Biochemical and structural studies have demonstrated that Axin binds to β-catenin at a site on armadillo repeats 3-5 and that Phe253 and Lys292 of β-catenin contribute to this interaction [35] [36] [37] . In our study, just as in the case of Wnt-mediated Axin inactivation, SKL2001 inhibited both the CK1-and GSK-3β-mediated phosphorylation of β-catenin at Ser45 and Ser33/37/Thr41, respectively, in HEK293 cells. Biochemical studies demonstrated that SKL2001 blocked the Axin/β-catenin interaction and competed with Axin for binding to β-catenin. Interestingly, molecular modeling predicted that SKL2001 binds to β-catenin at the same site as Axin via interaction with β-catenin residues Phe253 and Lys292 (Supplementary information, Figure S9 and Supplementary information method). Based on these results, we propose that SKL2001 selectively disrupts the Axin/β-catenin interaction, thereby inhibiting the CK1/GSK-3β-mediated phosphorylation of β-catenin at Ser33/37/Thr41 and Ser45. This unphosphorylated β-catenin is not targeted for degradation and accumulates in the cytoplasm, finally resulting in the activation of its downstream target genes ( Figure 6 ).
Previous studies implicate the Wnt/β-catenin pathway in the regulation of mesenchymal stem cell fate [38] . Transgenic mice expressing Wnt10b under the control of the adipose-specific fatty acid binding protein-4 (FABP4) promoter (FABP-Wnt10b) show a 50% decline in total body fat and are resistant to high-fat-diet-induced white adipose tissue accumulation [39] . In addition to reduced adiposity, FABP-Wnt10b mice exhibit an increase in bone mass [40] . Other evidence for a role of the Wnt/ β-catenin pathway in regulating mesenchymal stem cell differentiation is illustrated by the genetic deletion of the Wnt antagonist Sfrp1, which leads to a 20% reduction in body fat concomitant with increased bone mass [41] . Furthermore, treatments with pharmacological inhibitors of GSK-3β stabilize intracellular β-catenin, thereby stimulating osteoblastogenesis and blocking adipocyte differentiation [42, 43] . In the present study, disruption of the interaction of Axin and β-catenin by a small molecule, rather than inhibition of GSK-3β activity, promoted mesenchymal precursors to differentiate into osteoblasts and restrained adipocyte differentiation, mimicking the activation of the Wnt/β-catenin pathway.
In summary, we used high-throughput screening to identify a novel synthetic agonist of the Wnt/β-catenin pathway, which regulates the differentiation of mesenchymal stem cells. SKL2001 prevented the formation of the Axin/β-catenin complex, leading to inhibition of β-catenin phosphorylation/degradation. Because the Axin/β-catenin interaction is a key control point of the Wnt/β-catenin pathway, which plays important roles in cellular differentiation and development [27, 28] , SKL2001 can be used as a controllable reagent for investigating biological processes that involve this pathway, such as cell differentiation, stem cell renewal, and tissue regeneration. In addition, SKL2001 represents a promising candidate in the development of therapeutics for diseases associated with the abnormal regulation of the Wnt/β-catenin pathway.
Materials and Methods
Cell Culture, transfection, luciferase assay, alkaline phosphatase assay, alizarin red staining and oil-red O staining HEK293, ST2, 3T3L1 and Wnt3a-secreting L cells were obtained from the American Type Culture Collection and human mesenchymal stem cells were purchased from Cambrex Bio Science. The cells were maintained in Dulbecco's modified eagle medium supplemented with 10% fetal bovine serum, 120 µg/ml penicillin, and 200 µg/ml streptomycin. Wnt3a CM was prepared Figure 6 Proposed model for the disruption of the Axin/β-catenin interaction by SKL2001. β-catenin is phosphorylated by CK1/ GSK-3β when these proteins are in a complex with Axin. It is then degraded by the ubiquitin-dependent proteasomal pathway (left panel). SKL2001 promotes the dissociation of β-catenin from Axin, thereby stabilizing the protein through prevention of its phosphorylation with the end result of altering the regulation of mesenchymal stem cell differentiation.
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npg as previously described [44] . Transfection was carried out with Lipofectamine 2000 (Invitrogen) according to the manufacturer's instructions. Luciferase assays were performed using the Dual luciferase assay kit (Promega). ALP activity was determined in cell lysates with the Alkaline Phosphatase Opt Kit (Roche Meolecular Biochemicals). Mineralization of ST-2 cells was carried out by staining with 1% Alizarin red after fixation in 50% ethanol as previously described [45] . 3T3L1 preadipocytes were rinsed in PBS and fixed in 3.7% paraformaldehyde for 1 h at 4 °C. Briefly, plates were stained with 1% Oil Red O in 60% isopropanol for 10 min.
The stain was then differentiated with 60% isopropanol and plates were washed several times in distilled water prior to visualization under a phase-contrast microscope.
Screening for small-molecule activators of Wnt/β-catenin signaling
The HEK293 reporter and control cell lines were established as previously described [17] . The HEK293 reporter cells were inoculated into 384-well plates at 10 000 cells per well and grown for 24 h. Next, each compound in the chemical library (~270 000) was added to at a final concentration of 20 µM. After 15 h, the plates were assayed for firefly luciferase activity.
Plasmid and recombinant proteins
The pTOPflash and pFOPflash reporter plasmid was obtained from Upstate Biotechnology. pGEX-4T-1-β-catenin plasmid was a gift from Dr Woo Keun Song (GIST, Korea). Recombinant β-catenin, GSK-3β, CK1, and Axin (362-500) proteins were prepared as previously described [46, 47] .
Western blot analysis
The cytosolic and nuclear fraction was prepared as previously described [48] . Proteins were separated using 4-12% gradient SDS-PAGE (Invitrogen) and transferred to nitrocellulose membranes (Bio-Rad). The membranes were blocked with 5% nonfat milk and probed with anti-β-catenin (BD Transduction Laboratories), anti-phospho-β-catenin (Ser33/37/Thr41) (Cell Signaling Technology), anti-phospho-β-catenin (Thr41/Ser45) (Cell Signaling Technology), anti-Axin (BD Transduction Laboratories) and anti-actin antibodies (Cell Signaling Technology). The membranes were then incubated with horseradish peroxidase-conjugated antimouse IgG or anti-rabbit IgG (Santa Cruz Biotechnology) and visualized using the ECL system (Santa Cruz Biotechnology).
RNA extraction and semi-quantitative RT-PCR
Total RNA was isolated with Trizol reagent (Invitrogen) in accordance with the manufacturer's instructions. cDNA synthesis, reverse transcription, and PCR were performed as previously described [49] . The amplified DNA was separated on 2% agarose gels and stained with ethidium bromide.
In vitro kinase assay
Kinase assays were performed with purified CK1 and GSK-3 using purified GST-β-catenin (100 ng) as a substrate as previously described [46] . The proteins were subjected to SDS-PAGE and transferred onto nitrocellulose membranes. The transferred proteins were analyzed using western blotting with anti-phospho-β-catenin antibody (Cell Signaling Technology), and the membrane was exposed to X-ray film. In addition, kinase assays were conducted by Milipore's KinaseProfiler according to the manufacturer's protocols.
GST pull-down assay
Purified β-catenin-GST was mixed with 40 µM of SKL2001 in 500 µl of ADBII (20 mM MOPS, pH 7.2, 25 mM β-glycerol phosphate, 1 mM Na 3 VO 4 , 1 mM DTT, 1 mM CaCl 2 ) containing preequilibrated glutathione-Sepharose 4B beads, followed by incubation at 4 °C with gentle rotation. After 1 h, Axin (362-500) were added to the mixture and incubated 2h at 4 °C. Beads were then centrifuged at 600× g for 1 min and washed five times with 1 ml of PBS. Proteins bound to the beads were resuspended in 50 µl 2× LDS loading buffer and analyzed by western blotting for β-catenin and silver staining for Axin (362-500).
Silver staining SDS-PAGE gel was visualized by silver staining. The gel was placed in the fixing solution (50% methanol, 12% acetic acid) for 90min with gentle shaking. The gel is washed by 50% ethanol for 2 times (2 × 20 min) and then incubated in the sensitization solution containing 0.02% Na 2 S 2 O 3 for 1 min. Rinse the gel three times (1 min each) in water, incubate the gel in silver nitrate solution (1% AgNO 3 and 0.75 ml/l formalin (37%)) for 20 min. Discard silver nitrate solution and rinse twice in distilled water for 1 min each time. Develop the silver stain by soaking the gel in develop solution (Na 2 CO 3 , 0.0004% Na 2 S 2 O 3, 0.5 ml/l formalin (37%)) until bands appear. Development was stopped with 1% acetic acid.
Immunoprecipitation analysis
For immunoprecipitation experiments, HEK293 cells were transiently transfected with β-catenin and Axin and then treated with SKL2001. The final reaction volume was 500 µl, containing ~20 µl of protein A-agarose (Roche Diagnostics, Meylan, France), 200 µg of cell lysate, 1 µg of antibody and buffer A (10mM HEPES (pH 7.4 at 4 °C), 1.5 mM MgCl 2 , 10 mM KCl and 0.5 mM DTT) at 4 °C for overnight. Immunocomplexes were washed five times with PBS and boiled in the SDS-PAGE loading buffer, and the proteins were detected by western blotting.
Immunofluorescence analysis
ST2 cells were cultured on glass chamber slides and then treated with DMSO or SKL2001 for 15 h. After treatment, the cells were washed with PBS, fixed with 4% formaldehyde, permeabilized in 0.3% Triton X-100, and blocked in 4% bovine serum albumin for 1 h. The cells were stained with anti-β-catenin antibody and then analyzed by confocal microscopy using a Zeiss LSM510 Meta microscope.
